UK's medicine regulator said on Monday it has temporarily restricted the use of French vaccine maker Valneva's shot to treat ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...

Bavarian Nordic has commenced a Phase III trial of its chikungunya vaccine, CHIKV VLP, targeting the paediatric population ...

First children vaccinated in clinical study seeking to expand the target population for the chikungunya vaccine. COPENHAGEN, ...

A landmark global modeling study reveals that more than 2.8 billion people in 104 countries are at risk of chikungunya, with ...

The UK’s Medicines and Healthcare products Regulatory Agency said that following global reports of serious adverse events in ...

Results from the Phase II VLA1553-221 trial show that a full dose of Ixchiq demonstrated a 96.5% seroresponse rate in ...

Valneva has reported encouraging six-month safety and antibody persistence data from the multi-centre Phase II trial, VLA1553 ...

Following global reports of serious adverse events in older people, the government’s independent expert advisory body, the UK ...

Valneva reports positive six-month data for Ixchiq in children, supporting a full dose approach ahead of a Phase 3 trial set ...

First children vaccinated in clinical study seeking to expand the target population for the chikungunya vaccine. COPENHAGEN, Denmark, June 12, 2025 - Bavarian Nordic A/S (OMX: BAVA) announced ...

This is a precautionary measure while the MHRA conducts the safety review. Following global reports of serious adverse events ...